Search results for "Aminobutyrates"

showing 3 items of 23 documents

NEUROPHYSIOLOGICAL AND NEUROCHEMICAL STUDIES WITH THE ISONICOTINOYLHYDRAZONE OF PYRIDOXAL 5-PHOSPHATE.

1964

Pyridoxal 5-PhosphateBrain chemistryCarboxy-LyasesBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundNeurochemicalMesencephalonSeizuresCerebellumPonsIsoniazidPyridoxal phosphateTransaminasesBrain ChemistryPharmacologyMedulla OblongataGallamine TriethiodideChemistryAminobutyratesResearchBrainFrontal LobeElectrophysiologyBiochemistryPyridoxal PhosphateCatsJournal of neurochemistry
researchProduct

Molecular aggregation in selected crystalline 1:1 complexes of hydrophobicD- andL-amino acids. IV. TheL-phenylalanine series

2009

The amino acid L-phenylalanine has been cocrystallized with D-2-aminobutyric acid, C(9)H(11)NO(2).C(4)H(9)NO(2), D-norvaline, C(9)H(11)NO(2).C(5)H(11)NO(2), and D-methionine, C(9)H(11)NO(2).C(5)H(11)NO(2)S, with linear side chains, as well as with D-leucine, C(9)H(11)NO(2).C(6)H(13)NO(2), D-isoleucine, C(9)H(11)NO(2).C(6)H(13)NO(2), and D-allo-isoleucine, C(9)H(11)NO(2).C(6)H(13)NO(2), with branched side chains. The structures of these 1:1 complexes fall into two classes based on the observed hydrogen-bonding pattern. From a comparison with other L:D complexes involving hydrophobic amino acids and regular racemates, it is shown that the structure-directing properties of phenylalanine closel…

chemistry.chemical_classificationMolecular StructureChemistryStereochemistryAminobutyratesPhenylalanineHydrogen BondingStereoisomerismStereoisomerismPhenylalanineGeneral MedicineCrystallography X-RayGeneral Biochemistry Genetics and Molecular BiologyAmino acidValineSide chainIsoleucineLeucineAminobutyratesHydrophobic and Hydrophilic InteractionsActa Crystallographica Section C Crystal Structure Communications
researchProduct

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

2019

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…

medicine.medical_specialtyMEDLINETetrazolesHeart failureLifeInternal MedicinemedicineHumansKidney dysfunctionSacubitril-ValsartanIntensive care medicinebusiness.industryAminobutyratesBiphenyl CompoundsFollow up studiesSacubitril/Valsartanmedicine.diseaseIm - OriginalDrug CombinationsValsartanHeart failureBlood pressureEmergency MedicineValsartanbusinessSacubitril ValsartanFollow-Up StudiesRenal functionmedicine.drug
researchProduct